Life Scientist > Lab Technology

Up to his own devices: Alan Finkel on life after Axon

26 July, 2004 by Melissa Trudinger

Ask Alan Finkel what he would do differently if he started another company, and he’s quick to reply. “I wouldn’t start another company overseas,” he says.


Amrad shareholders stock up

22 July, 2004 by Melissa Trudinger

Some of Amrad's larger shareholders are boosting their holdings in the Melbourne company (ASX:AML), as long-time Japanese investor Chugai divests itself of its 10 per cent stake in the company.


Good Start for local businesses

22 July, 2004 by Iain Scott

Life science companies - from start-ups to listed biotechs - featured highly in the latest round of Commonwealth R&D Start funding, it was revealed yesterday.


Few dauntless biotechs still queuing for IPOs

20 July, 2004 by Melissa Trudinger

Mixed results from recent IPOs in the Australian and international biotech sectors have not daunted several local biotechs' plans to list on the ASX in coming months.


PanBio raising restricted to $1m

16 July, 2004 by Melissa Trudinger

A softening market and a low share price have had an impact on PanBio's (ASX:PBO) recently completed share purchase plan offering to shareholders, which has raised just under AUD$1 million out of a possible $4.2 million.


Lorne conferences move offshore

16 July, 2004 by Melissa Trudinger

Next year's Lorne conferences, the traditional summer high point for Australian life science researchers, will not be held at Lorne.


Psivida wins technology award

15 July, 2004 by Melissa Trudinger

Nanotechnology company Psivida (ASX: PSD) has had its research applying its BioSilicon technology to drug delivery, diagnostics, orthopaedics and tissue engineering recognised with a 2004 Excellence in Research Award from US consulting group Frost & Sullivan.


Four of the best: pSiVida, Progen, AustCancer, Anadis

08 July, 2004 by Graeme O'Neill

Three Australian biotechnology companies logged share price gains of over 300 per cent this financial year: pSivida (ASX: PSD) soared 387 per cent, Progen (ASX:PGL) was up 368 per cent and Australian Cancer Technology (ASX:ACU) was up 316 per cent. Biopharmaceutical company Anadis (ASX:ANX) also hit its stride, its share price rising 177 per cent.


Size isn't everything in nanotechnology

08 July, 2004 by Melissa Trudinger

Nanobiotechnology is one of the main opportunities for Australia to develop capabilities in nanotechnology, the CEO of Nanotechnology Victoria (Nanovic) Peter Binks said today.


Schofield leaves Garvan to join Prince of Wales

07 July, 2004 by Renate Krelle

Neuroscience and mental illness specialist Prof Peter Schofield has been appointed executive director and CEO of the Prince of Wales Medical Research Institute, and plans to move his 15-strong research team from the Garvan Institute to yet-to-be-built labs in Sydney’s Randwick.


IDT scores Pfizer contract

05 July, 2004 by Melissa Trudinger

The Institute of Drug Technology (ASX: IDT) has scored a multi-million dollar contract with Pfizer to develop and manufacture a new drug candidate.


Scottish biotech Cyclacel joins IPO bandwagon

05 July, 2004 by Staff Writers

Scottish cancer specialist Cyclacel has announced plans to float on Nasdaq and the London Stock Exchange.


LEK's McIntyre joins BioTech Capital board

01 July, 2004 by Iain Scott

Dr Lisa McIntyre, the head of LEK Consulting's Asia-Pacific life sciences practice, has joined the board of Sydney-based pooled development fund BioTech Capital (ASX:BTC).


NSW, feds to fund Sydney medical research complex

30 June, 2004 by Renate Krelle

Sydney's Victor Chang Cardiac Research Institute will get new digs, the Garvan Institute will get its building back, and both will be sharing café and confocal microscopy facilities with researchers from over the road at St Vincent's Hospital, if a $46 million new laboratory building gets underway.


From grapes to grants: new ARC head outlines plans

30 June, 2004 by Susan Williamson

Prof Peter Høj, currently director of the Australian Wine Research Institute, has been appointed the new CEO of the Australian Research Council (ARC).


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd